Your browser doesn't support javascript.
loading
Efficacy and safety of raltegravir plus lamivudine maintenance therapy.
Borjabad, Beatriz; Inciarte, Alexy; Chivite, Ivan; Gonzalez-Cordon, Ana; Mosquera, Mar; Hurtado, Carmen; Rovira, Cristina; Gonzalez, Tania; Sempere, Abiu; Torres, Berta; Calvo, Julia; De La Mora, Lorena; Martinez-Rebollar, Maria; Laguno, Montserrat; Foncillas, Alberto; Ambrosioni, Juan; Blanch, Jordi; Rodriguez, Ana; Solbes, Estela; Llobet, Roger; Berrocal, Leire; Mallolas, Josep; Miro, Jose M; Alcami, Jose; Blanco, Jose L; Sanchez-Palomino, Sonsoles; De Lazzari, Elisa; Martinez, Esteban.
Affiliation
  • Borjabad B; Internal Medicine Service, Hospital Moises Broggi, Sant Joan Despí, Spain.
  • Inciarte A; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Chivite I; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Gonzalez-Cordon A; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Mosquera M; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Hurtado C; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Rovira C; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Gonzalez T; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Sempere A; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Torres B; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Calvo J; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • De La Mora L; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Martinez-Rebollar M; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Laguno M; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Foncillas A; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Ambrosioni J; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Blanch J; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Rodriguez A; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Solbes E; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Llobet R; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Berrocal L; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Mallolas J; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Miro JM; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Alcami J; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Blanco JL; Internal Medicine Service, Hospital Universitari de Santa Maria, Lleida, Spain.
  • Sanchez-Palomino S; CIBER de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.
  • De Lazzari E; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
  • Martinez E; Infectious Diseases Unit, Hospital Clínic, University of Barcelona 08036, Barcelona, Spain.
J Antimicrob Chemother ; 79(2): 255-261, 2024 Feb 01.
Article in En | MEDLINE | ID: mdl-38039097
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents / Drug-Related Side Effects and Adverse Reactions Limits: Humans Language: En Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents / Drug-Related Side Effects and Adverse Reactions Limits: Humans Language: En Year: 2024 Type: Article